Q4 2025 · 13F-HR
Column Group LLCholdings as filed
Filed 2026-02-13 · accession 0001193125-26-051393
$82.8M
Reported value
5
Positions
2025-12-31
Period end
The Brief · Column Group LLC · Q4 2025
AI · grounded in 13F
Column Group LLC increased its position in Surrozen, Inc. by 23.442%. The fund also trimmed its holding in RAPT Therapeutics Inc RAPT by 5.904%. Total assets under management stood at $82,793,614 across five positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 86889P109 | — | Surrozen, Inc. | $41.8M | 50.5% | 1,851,350 | Common | SOLE |
| 68622P109 | ORIC | ORIC Pharmaceuticals Inc. | $29.0M | 35.0% | 3,540,777 | Common | SOLE |
| 87990A106 | TNYA | Tenaya Therapeutics, Inc. | $6.7M | 8.08% | 9,400,290 | Common | SOLE |
| 75382E109 | — | RAPT Therapeutics Inc | $5.3M | 6.39% | 156,270 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines Inc | $3,664 | 0.00% | 46 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.